modelLamivudineAndDolutegravi
Extends from Pharmacolibrary.Drugs.ATC.J.J05AR25.
Information
| name: | LamivudineAndDolutegravir | |
| ATC code: | J05AR25 | route: | oral |
| compartments: | 1 | |
| dosage: | 350 | mg |
| volume of distribution: | 17.8 | L |
| clearance: | 1.0 | L/h |
| other parameters in model implementation | ||
Lamivudine and dolutegravir is a fixed-dose combination antiretroviral medication used for the treatment of HIV-1 infection. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI), while dolutegravir is an integrase strand transfer inhibitor (INSTI). This combination is approved and widely used as a once-daily regimen in adults and adolescents for HIV therapy.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult subjects receiving oral administration of the fixed dose combination (lamivudine 300 mg, dolutegravir 50 mg) as a single dose.
References
Singh, RP, et al., & Wynne, B (2021). Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of Abacavir/Dolutegravir/Lamivudine Combination Tablets in Healthy Japanese Study Participants. Clinical pharmacology in drug development 10(9) 985–993. DOI:10.1002/cpdd.996 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34265164
Chandasana, H, et al., & Pene Dumitrescu, T (2024). Population pharmacokinetic modeling of dolutegravir/lamivudine to support a once-daily fixed-dose combination regimen in virologically suppressed adults living with HIV-1. Antimicrobial agents and chemotherapy 68(5) e0150423–None. DOI:10.1128/aac.01504-23 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38587380
Singh, RP, et al., & Buchanan, AM (2022). Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children. The Pediatric infectious disease journal 41(3) 230–237. DOI:10.1097/INF.0000000000003366 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34817414
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)